Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Change in Accured Expenses: 2019-2025

Historic Change in Accured Expenses for Biodesix (BDSX) over the last 6 years, with Sep 2025 value amounting to $486,000.

  • Biodesix's Change in Accured Expenses fell 21.86% to $486,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 266.86%. This contributed to the annual value of $1.6 million for FY2024, which is 219.10% up from last year.
  • Per Biodesix's latest filing, its Change in Accured Expenses stood at $486,000 for Q3 2025, which was down 79.20% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Biodesix's Change in Accured Expenses registered a high of $3.3 million during Q2 2023, and its lowest value of -$5.7 million during Q1 2021.
  • Moreover, its 3-year median value for Change in Accured Expenses was $555,000 (2024), whereas its average is $275,909.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first crashed by 770.25% in 2021, then skyrocketed by 2,897.25% in 2023.
  • Over the past 5 years, Biodesix's Change in Accured Expenses (Quarterly) stood at $1.8 million in 2021, then plummeted by 106.91% to -$127,000 in 2022, then spiked by 698.43% to $760,000 in 2023, then skyrocketed by 122.89% to $1.7 million in 2024, then declined by 21.86% to $486,000 in 2025.
  • Its Change in Accured Expenses was $486,000 in Q3 2025, compared to $2.3 million in Q2 2025 and -$1.9 million in Q1 2025.